Antiviral therapy for hepatitis C: Has anything changed for pregnant/lactating women?

PMC full text:

World J Hepatol. 2016 Apr 28; 8(12): 557–565.

Published online 2016 Apr 28. doi: 10.4254/wjh.v8.i12.557

Table 2

Effect of new direct-acting antivirals in pregnancy and Food and Drug Administration Pregnancy Categories

Drug		Embryotoxicity and/or teratogenicity¹	Dose-escalation²	Transfer across placenta	Transfer into milk	FDA Pregnancy Category³
Sofosbuvir		No	28-fold	Yes	Yes	B
Simeprevir		Yes	4-fold	Yes	Yes	C
Daclatasvir		Yes	4-fold	Yes	Yes	NA⁴
Ledipasvir		No	Maternal toxic doses	Yes	Yes	B
Viekirax	Ombitasvir	Yes	4-fold	Minimal	Yes	B
	Paritaprevir		32-fold
	Ritonavir		8-fold
Dasabuvir		No	48-fold	Minimal	Yes	B

¹Based on animal studies;

²Dose escalation above therapeutic dose;

³FDA Pregnancy Category without association with ribavirin. NA: Not available; FDA: The Food and Drug Administration.